Drugs / BMS-986226
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03251924 | Sep 2017 → Dec 2021 | cancer | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03251924 ↗ |
| Route | Intravenous | “administered intravenously” NCT03251924 ↗ |